Retatrutide and trizepatide are a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists demonstrate https://janeadsx639892.loginblogin.com/profile